Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

The importance of irritability as a symptom of major depressive disorder: results from the National Comorbidity Survey Replication

Abstract

Irritability is a diagnostic symptom of major depressive disorder (MDD) in children and adolescents but not in adults in both the Diagnostic and Statistical Manual of Mental Disorders, fourth edition (DSM-IV) and International Classification of Diseases (ICD-10) systems. We explore the importance of irritability for subtyping adult DSM-IV MDD in the National Comorbidity Survey Replication (NCS-R), a national US adult household survey. The WHO Composite International Diagnostic Interview (CIDI) was used to assess prevalence of many DSM-IV disorders in the lifetime and in the year before interview (12-month prevalence). MDD was assessed conventionally (that is, requiring either persistent sadness or loss of interest), but with irritability included as one of the Criterion A symptoms. We also considered the possibility that irritability might be a diagnostic symptom of adult MDD (that is, detect cases who had neither sad mood nor loss of interest). Twelve-month MDD symptom severity was assessed with the Quick Inventory of Depressive Symptomatology and role impairment with the Sheehan Disability Scale. After excluding bipolar spectrum disorders, irritability during depressive episodes was reported by roughly half of respondents with lifetime DSM-IV MDD. Irritability in the absence of either sad mood or loss of interest, in comparison, was rare. Irritability in MDD was associated with early age of onset, lifetime persistence, comorbidity with anxiety and impulse-control disorders, fatigue and self-reproach during episodes, and disability. Irritability was especially common in MDD among respondents in the age range 18–44 and students. Further investigation is warranted of distinct family aggregation, risk factors and treatment response. Consideration should also be given to including irritability as a nondiagnostic symptom of adult MDD in DSM-V and ICD-11.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy article

Get time limited or full article access on ReadCube.

$32.00

All prices are NET prices.

Figure 1

References

  1. Crowe M, Ward N, Dunnachie B, Roberts M . Characteristics of adolescent depression. Int J Ment Health Nurs 2006; 15: 10–18.

    Article  PubMed  Google Scholar 

  2. Ryan ND, Puig-Antich J, Ambrosini P, Rabinovich H, Robinson D, Nelson B et al. The clinical picture of major depression in children and adolescents. Arch Gen Psychiatry 1987; 44: 854–861.

    Article  CAS  PubMed  Google Scholar 

  3. Fava GA, Grandi S, Canestrari R, Molnar G . Prodromal symptoms in primary major depressive disorder. J Affect Disord 1990; 19: 149–152.

    Article  CAS  PubMed  Google Scholar 

  4. Perlis RH, Fraguas R, Fava M, Trivedi MH, Luther JF, Wisniewski SR et al. Prevalence and clinical correlates of irritability in major depressive disorder: a preliminary report from the Sequenced Treatment Alternatives to Relieve Depression study. J Clin Psychiatry 2005; 66: 159–166.

    Article  PubMed  Google Scholar 

  5. Snaith RP, Taylor CM . Irritability: definition, assessment and associated factors. Br J Psychiatry 1985; 147: 127–136.

    Article  CAS  PubMed  Google Scholar 

  6. Fava M, Alpert J, Nierenberg AA, Ghaemi N, O'Sullivan R, Tedlow J et al. Fluoxetine treatment of anger attacks: a replication study. Ann Clin Psychiatry 1996; 8: 7–10.

    Article  CAS  PubMed  Google Scholar 

  7. Fava M, Nierenberg AA, Quitkin FM, Zisook S, Pearlstein T, Stone A et al. A preliminary study on the efficacy of sertraline and imipramine on anger attacks in atypical depression and dysthymia. Psychopharmacol Bull 1997; 33: 101–103.

    CAS  PubMed  Google Scholar 

  8. Fava M, Rosenbaum JF, Pava JA, McCarthy MK, Steingard RJ, Bouffides E . Anger attacks in unipolar depression, Part 1: clinical correlates and response to fluoxetine treatment. Am J Psychiatry 1993; 150: 1158–1163.

    Article  CAS  PubMed  Google Scholar 

  9. Kessler RC, Merikangas KR . The National Comorbidity Survey Replication (NCS-R): background and aims. Int J Methods Psychiatr Res 2004; 13: 60–68.

    Article  PubMed  Google Scholar 

  10. Kessler RC, McGonagle KA, Zhao S, Nelson CB, Hughes M, Eshleman S et al. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey. Arch Gen Psychiatry 1994; 51: 8–19.

    Article  CAS  PubMed  Google Scholar 

  11. First MB, Spitzer RL, Gibbon M, Williams JBW . Structured Clinical Interview for DSM-IV-TR Axis I Disorders, Research Version, Non-Patient Edition (SCID-I/NP). Biometrics Research, New York State Psychiatric Institute: New York, NY, 2002.

    Google Scholar 

  12. Kessler RC, Berglund P, Chiu WT, Demler O, Heeringa S, Hiripi E et al. The US National Comorbidity Survey Replication (NCS-R): design and field procedures. Int J Methods Psychiatr Res 2004; 13: 69–92.

    Article  PubMed  Google Scholar 

  13. Kessler RC, Ustun TB . The World Mental Health (WMH) Survey Initiative Version of the World Health Organization (WHO) Composite International Diagnostic Interview (CIDI). Int J Methods Psychiatr Res 2004; 13: 93–121.

    Article  PubMed  Google Scholar 

  14. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (DSM-IV), 4th edn. American Psychiatric Association: Washington, DC, 1994.

  15. Rush AJ, Carmody T, Reimitz PE . The inventory of depressive symptomatology (IDS): Clinician (IDS-C) and self-report (IDS-SR) ratings of depressive symptoms. Int J Methods Psychiatr Res 2000; 9: 45–59.

    Article  Google Scholar 

  16. Rush AJ, Gullion CM, Basco MR, Jarrett RB, Trivedi MH . The Inventory of Depressive Symptomatology (IDS): psychometric properties. Psychol Med 1996; 26: 477–486.

    Article  CAS  PubMed  Google Scholar 

  17. Hamilton M . A rating scale for depression. J Neurol Neurosurg Psychiatry 1960; 23: 56–62.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Rush AJ, Trivedi MH, Ibrahim HM, Carmody TJ, Arnow B, Klein DN et al. The 16-Item Quick Inventory of Depressive Symptomatology (QIDS), clinician rating (QIDS-C), and self-report (QIDS-SR): a psychometric evaluation in patients with chronic major depression. Biol Psychiatry 2003; 54: 573–583.

    Article  PubMed  Google Scholar 

  19. Leon AC, Olfson M, Portera L, Farber L, Sheehan DV . Assessing psychiatric impairment in primary care with the Sheehan Disability Scale. Int J Psychiatry Med 1997; 27: 93–105.

    Article  CAS  PubMed  Google Scholar 

  20. SAS Institute. SAS 9.1.3 Help and Documentation. SAS Publishing: Cary, NC, 2002.

  21. Wolter KM . Introduction to Variance Estimation. Springer-Verlag: New York, 1985.

    Google Scholar 

  22. Research Triangle Institute. SUDAAN: Professional Software for Survey Data Analysis. 8.01 edn. Research Triangle Institute: Research Triangle Park, NC, 2002.

  23. Fava GA, Pilowsky I, Pierfederici A, Bernardi M, Pathak D . Depressive symptoms and abnormal illness behavior in general hospital patients. Gen Hosp Psychiatry 1982; 4: 171–178.

    Article  CAS  PubMed  Google Scholar 

  24. Merikangas KR, Akiskal HS, Angst J, Greenberg PE, Hirschfeld RM, Petukhova M et al. Lifetime and 12-month prevalence of bipolar spectrum disorder in the National Comorbidity Survey replication. Arch Gen Psychiatry 2007; 64: 543–552.

    Article  PubMed  PubMed Central  Google Scholar 

  25. Benazzi F . Major depressive disorder with anger: a bipolar spectrum disorder? Psychother Psychosom 2003; 72: 300–306.

    Article  PubMed  Google Scholar 

  26. Akiskal HS . The emergence of the bipolar spectrum:validation along clinical-epidemiologic and familial-genetic lines. Psychopharmacol Bull 2007; 40: 99–115.

    PubMed  Google Scholar 

  27. Bauer M, Pfennig A . Epidemiology of bipolar disorders. Epilepsia 2005; 46 (Suppl 4): 8–13.

    Article  PubMed  Google Scholar 

  28. Benazzi F . Possible bipolar nature of irritability in major depressive disorder. J Clin Psychiatry 2005; 66: 1072; author reply 1073.

    Article  PubMed  Google Scholar 

  29. Benazzi F, Akiskal H . Irritable-hostile depression: further validation as a bipolar depressive mixed state. J Affect Disord 2005; 84: 197–207.

    Article  PubMed  Google Scholar 

  30. Alpert JE, Petersen T, Roffi PA, Papakostas GI, Freed R, Smith MM et al. Behavioral and emotional disturbances in the offspring of depressed parents with anger attacks. Psychother Psychosom 2003; 72: 102–106.

    Article  PubMed  Google Scholar 

  31. Perris C . The distinction between unipolar and bipolar mood disorders. A 25-years perspective. Encephale 1992; 18 (Spec no. 1): 9–13.

    PubMed  Google Scholar 

  32. Yoshimasu K, Sugahara H, Tokunaga S, Akamine M, Kondo T, Fujisawa K et al. Gender differences in psychiatric symptoms related to suicidal ideation in Japanese patients with depression. Psychiatry Clin Neurosci 2006; 60: 563–569.

    Article  PubMed  Google Scholar 

  33. Fava M, Rush AJ, Alpert JE, Carmin CN, Balasubramani GK, Wisniewski SR et al. What clinical and symptom features and comorbid disorders characterize outpatients with anxious major depressive disorder: a replication and extension. Can J Psychiatry 2006; 51: 823–835.

    Article  PubMed  Google Scholar 

  34. Swanson JW, Holzer III CE, Ganju VK, Jono RT . Violence and psychiatric disorder in the community: evidence from the Epidemiologic Catchment Area surveys. Hosp Community Psychiatry 1990; 41: 761–770.

    CAS  PubMed  Google Scholar 

  35. Sher L, Oquendo MA, Li S, Ellis S, Brodsky BS, Malone KM et al. Prolactin response to fenfluramine administration in patients with unipolar and bipolar depression and healthy controls. Psychoneuroendocrinology 2003; 28: 559–573.

    Article  CAS  PubMed  Google Scholar 

  36. Davis LL, Clark DM, Kramer GL, Moeller FG, Petty F . D-fenfluramine challenge in posttraumatic stress disorder. Biol Psychiatry 1999; 45: 928–930.

    Article  CAS  PubMed  Google Scholar 

  37. New AS, Trestman RF, Mitropoulou V, Goodman M, Koenigsberg HH, Silverman J et al. Low prolactin response to fenfluramine in impulsive aggression. J Psychiatr Res 2004; 38: 223–230.

    Article  PubMed  Google Scholar 

  38. Fava M, Vuolo RD, Wright EC, Nierenberg AA, Alpert JE, Rosenbaum JF . Fenfluramine challenge in unipolar depression with and without anger attacks. Psychiatry Res 2000; 94: 9–18.

    Article  CAS  PubMed  Google Scholar 

  39. Dougherty DD, Rauch SL, Deckersbach T, Marci C, Loh R, Shin LM et al. Ventromedial prefrontal cortex and amygdala dysfunction during an anger induction positron emission tomography study in patients with major depressive disorder with anger attacks. Arch Gen Psychiatry 2004; 61: 795–804.

    Article  PubMed  Google Scholar 

Download references

Acknowledgements

The National Comorbidity Survey Replication (NCS-R) was supported by the National Institute of Mental Health (NIMH; U01-MH60220) with supplemental support from the National Institute of Drug Abuse, the Substance Abuse and Mental Health Services Administration, the Robert Wood Johnson Foundation (Grant No. 044780) and the John W Alden Trust. Collaborating NCS-R investigators include Ronald C Kessler (Principal Investigator, Harvard Medical School), Kathleen Merikangas (Co-principal Investigator, NIMH), James Anthony (Michigan State University), William Eaton (The Johns Hopkins University), Meyer Glantz (NIDA), Doreen Koretz (Harvard University), Jane McLeod (Indiana University), Mark Olfson (Columbia University College of Physicians and Surgeons), Harold Pincus (University of Pittsburgh), Greg Simon (Group Health Cooperative), T Bedirhan Ustun (World Health Organization), Michael Von Korff (Group Health Cooperative), Philip Wang (Harvard Medical School), Kenneth Wells (UCLA), Elaine Wethington (Cornell University) and Hans-Ulrich Wittchen (Max Planck Institute of Psychiatry). The views and opinions expressed in this report are those of the authors and should not be construed to represent the views of any of the sponsoring organizations, agencies or US Government. A complete list of NCS publications and the full text of all NCS-R instruments can be found at http://www.hcp.med.harvard.edu/ncs. Send correspondence to NCS@hcp.med.harvard.edu. The NCS-R is carried out in conjunction with the World Health Organization World Mental Health (WMH) Survey Initiative. We thank the staff of the WMH Data Collection and Data Analysis Coordination Centers for assistance with instrumentation, fieldwork and consultation on data analysis. These activities were supported by the John D and Catherine T MacArthur Foundation, the Pfizer Foundation, the US Public Health Service (R13MH066849, R01-MH069864 and R01 DA016558), Eli Lilly and Company, GlaxoSmithKline, Ortho-McNeil Pharmaceutical Inc. and the Pan American Health Organization. A complete list of WMH publications and instruments can be found at (http://www.hcp.med.harvard.edu/wmhcidi).

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to R C Kessler.

Additional information

Financial Disclosures

Dr Fava has research support from Abbott Laboratories, Alkermes, Aspect Medical Systems, AstraZeneca, Bristol-Myers Squibb Company, Cephalon, Eli Lilly and Company, Forest Pharmaceuticals Inc., GlaxoSmithKline, Johnson & Johnson Pharmaceuticals, Lichtwer Pharma GmbH, Lorex Pharmaceuticals, Novartis, Organon Inc., PamLab LLC, Pfizer Inc., Pharmavite, Roche, Sanofi-Synthelabo, Solvay Pharmaceuticals Inc. and Wyeth-Ayerst Laboratories. He has served as an advisor/consultant for Aspect Medical Systems, AstraZeneca, Bayer AG, Biovail Pharmaceuticals Inc., BrainCells Inc., Bristol-Myers Squibb Company, Cephalon, Comellas, Cypress Pharmaceuticals, DOV Pharmaceuticals, Eli Lilly and Company, EPIX Pharmaceuticals, Fabre-Kramer Pharmaceuticals Inc., Forest Pharmaceuticals Inc., GlaxoSmithKline, Grunenthal GmbH, Janssen Pharmaceutica, Jazz Pharmaceuticals Inc., Johnson & Johnson Pharmaceuticals, Knoll Pharmacuetical Company, Lundbeck, MedAvante Inc., Merck, Neuronetics, Novartis, Nutrition 21, Organon Inc., PamLab LLC, Pfizer Inc., PharmaStar, Pharmavite, Roche, Sanofi-Synthelabo, Sepracor, Solvay Pharmaceuticals Inc., Somaxon, Somerset Pharmaceuticals and Wyeth-Ayerst Laboratories. He has been on speaker bureaus for AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb Company, Cephalon, Eli Lilly and Company, Forest Pharmaceuticals Inc., GlaxoSmithKline, Novartis, Organon Inc., Pfizer Inc., PharmaStar and Wyeth-Ayerst Laboratories. He holds equity in Compellis and MedAvante. Dr Kessler has been a consultant for GlaxoSmithKline Inc., Pfizer Inc., Wyeth-Ayerst, Sanofi-Aventis, Kaiser Permanente and Shire Pharmaceuticals; has served on advisory boards for Eli Lilly and Company and Wyeth-Ayerst; and has had research support for his epidemiological studies from Bristol-Myers Squibb, Eli Lilly and Company, GlaxoSmithKline, Johnson & Johnson Pharmaceuticals, Ortho-McNeil Pharmaceuticals Inc., Pfizer Inc. and Sanofi-Aventis. Dr Rush has provided scientific consultation to or served on Advisory Boards for Advanced Neuromodulation Systems Inc., AstraZeneca, Best Practice Project Management Inc., Bristol-Myers Squibb Company/Otsuka, Cyberonics Inc., Forest Pharmaceuticals, GlaxoSmithKline, Jazz Pharmaceuticals, Eli Lilly and Company, Magellan Health Services, Merck & Co. Inc., Neuronetics, Novartis, Ono Pharmaceutical, Organon Inc., Pamlab Pfizer Inc. and Transcept Pharmaceuticals. He has received royalties from Guilford Press and Healthcare Technology Systems and research/grant support from the National Institute of Mental Health and the Stanley Medical Research Institute; has been on speaker bureaus for Cyberonics Inc., Forest Pharmaceuticals Inc. and GlaxoSmithKline; and owned stock in Pfizer Inc.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Fava, M., Hwang, I., Rush, A. et al. The importance of irritability as a symptom of major depressive disorder: results from the National Comorbidity Survey Replication. Mol Psychiatry 15, 856–867 (2010). https://doi.org/10.1038/mp.2009.20

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/mp.2009.20

Keywords

  • epidemiology
  • irritability
  • major depressive disorder
  • National Comorbidity Survey Replication
  • adult

This article is cited by

Search

Quick links